Hero Image

Innovative Obesity Treatment

ERX Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a first-in-class oral leptin sensitizer based on a new understanding of the biology of obesity.
37 catens outline copyCreated with Sketch.

Research & Development

Leptin Resistance & Obesity

Leptin is a hormone produced by fat cells that mediates body weight by telling the brain how much to eat and how much energy to expend. Higher leptin levels signal the brain to reduce food intake and increase energy expenditure. Research demonstrating that exogeneous administration of leptin is ineffective as a treatment for obesity suggests that obesity is a condition not of leptin deficiency, but rather one of leptin resistance. That’s why ERX is developing ERX-1000, a leptin sensitizer.
dna-outline-94Created with Sketch.

News

Latest News

At the ObesityWeek 2026 conference, ERX announced positive results showing that leptin sensitizer ERX1000, when combined with GLP-1 medication semaglutide, significantly enhanced weight loss, muscle strength and overall metabolic health in diet-induced obese mice.

About ERX-1000


About Obesity & Related Diseases


Company Milestones